AR115898A1 - 1,7-naftiridinas como inhibidores de cdk8/19 - Google Patents

1,7-naftiridinas como inhibidores de cdk8/19

Info

Publication number
AR115898A1
AR115898A1 ARP190102200A ARP190102200A AR115898A1 AR 115898 A1 AR115898 A1 AR 115898A1 AR P190102200 A ARP190102200 A AR P190102200A AR P190102200 A ARP190102200 A AR P190102200A AR 115898 A1 AR115898 A1 AR 115898A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
substituted
substituents
alkyl
nr19r20
Prior art date
Application number
ARP190102200A
Other languages
English (en)
Spanish (es)
Inventor
Dmitry Valentinovich Morozov
Pavel Andreevich Iakovlev
Evgenii Jurevich Smirnov
Sergei Aleksandrovich Silonov
Mariia Sergeevna Mishina
Elena Aleksandrovna Maksimenko
Liliana Vyacheslavovna Lenshmidt
Anton Aleksandrovich Evdokimov
Aleksei Sergeevich Gavrilov
Andrei Ivanovich Alafinov
Mariia Andreevna Kasatkina
Anna Jurevna Chestnova
Aleksei Leonidovich Mindich
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR115898A1 publication Critical patent/AR115898A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP190102200A 2018-08-03 2019-08-02 1,7-naftiridinas como inhibidores de cdk8/19 AR115898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19

Publications (1)

Publication Number Publication Date
AR115898A1 true AR115898A1 (es) 2021-03-10

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102200A AR115898A1 (es) 2018-08-03 2019-08-02 1,7-naftiridinas como inhibidores de cdk8/19

Country Status (19)

Country Link
US (1) US11840531B2 (cg-RX-API-DMAC7.html)
EP (1) EP3831829A4 (cg-RX-API-DMAC7.html)
JP (1) JP7365396B2 (cg-RX-API-DMAC7.html)
KR (1) KR102926889B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166140B (cg-RX-API-DMAC7.html)
AR (1) AR115898A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019313199B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001939A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108298A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000282A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021001174A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190452A1 (cg-RX-API-DMAC7.html)
MA (1) MA52375B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001335A (cg-RX-API-DMAC7.html)
PE (1) PE20210416A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550258A1 (cg-RX-API-DMAC7.html)
RU (1) RU2761824C2 (cg-RX-API-DMAC7.html)
TW (1) TWI839374B (cg-RX-API-DMAC7.html)
WO (1) WO2020027704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2229375A1 (en) 2007-12-06 2010-09-22 Schering Corporation Gamma secretase modulators
EP2630122B1 (en) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Arylamide derivatives as ttx-s blockers
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-萘啶衍生物
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 新規ナフチリジン及びイソキノリンならびにcdk8/19阻害剤としてのその使用
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
EP3464267B1 (en) * 2016-05-23 2020-09-23 Boehringer Ingelheim International GmbH New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Also Published As

Publication number Publication date
KR102926889B1 (ko) 2026-02-19
CN113166140A (zh) 2021-07-23
MA52375B2 (fr) 2023-02-28
US11840531B2 (en) 2023-12-12
CL2021000282A1 (es) 2021-08-13
PH12021550258A1 (en) 2021-10-11
JP2021533143A (ja) 2021-12-02
RU2018128415A3 (cg-RX-API-DMAC7.html) 2021-03-30
CA3108298A1 (en) 2020-02-06
AU2019313199A1 (en) 2021-03-11
BR112021001939A2 (pt) 2021-04-27
WO2020027704A1 (ru) 2020-02-06
CO2021001174A2 (es) 2021-02-26
KR20210040416A (ko) 2021-04-13
CN113166140B (zh) 2024-06-14
RU2761824C2 (ru) 2021-12-13
EP3831829A1 (en) 2021-06-09
AU2019313199B2 (en) 2023-07-06
US20210246138A1 (en) 2021-08-12
PE20210416A1 (es) 2021-03-04
TW202012406A (zh) 2020-04-01
EP3831829A4 (en) 2022-04-20
TWI839374B (zh) 2024-04-21
EA202190452A1 (ru) 2021-04-13
RU2018128415A (ru) 2020-02-04
JP7365396B2 (ja) 2023-10-19
MX2021001335A (es) 2021-04-12
MA52375A1 (fr) 2021-12-31

Similar Documents

Publication Publication Date Title
AR111776A1 (es) Heteroarilos inhibidores de las proteínas ras mutantes de g12c
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR115646A1 (es) Inhibidores de quinasas dependientes de ciclinas
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR088293A1 (es) Inhibidores de proteina cinasa
AR103561A1 (es) Fenilpiridinas herbicidas
AR106763A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR100879A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR098492A1 (es) Derivados de purina
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
AR117900A1 (es) Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR111271A1 (es) Inhibidores dobles de magl y faah
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR113888A1 (es) Derivados de indol macrocíclicos sustituidos
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2
AR093796A1 (es) Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa
AR089782A1 (es) Derivados heterociclicos biciclicos, su preparacion y su aplicacion en terapeutica